Necuparanib: Phase I/II delayed

Momenta temporarily paused enrollment in the Phase II portion of a double-blind, placebo-controlled, North American Phase I/II trial of oral necuparanib following an independent DSMB recommendation. The company expects to resume enrollment after instituting a protocol amendment that will standardize its methods for diagnosing and managing thrombocytopenia. The DSMB recommended the measures after it discussed thrombocytopenia, risk of bleeding and thromboembolic events. ...